Neos Therapeutics (Neos Therapeutics) ROCE % : 0.00% (As of Sep. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neos Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2020 was 0.00%.

Neos Therapeutics ROCE % Historical Data

The historical data trend for Neos Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics ROCE % Chart

Neos Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

ROCE %

Get a 7-Day Free Trial

-37.02

-91.86

-86.13

-68.29

-21.72

Neos Therapeutics Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
ROCE %	Get a 7-Day Free Trial															-2.32	-19.80	-98.12	-121.44	-

Neos Therapeutics ROCE % Calculation

Neos Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2019 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2019 )		(A: Dec. 2018 )		(A: Dec. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2019 )		(A: Dec. 2018 )		(A: Dec. 2019 )
	=	-8.882	/	( ( (111.357 - 57.105)	+	(90.873 - 63.355) )	/ 2 )
	=	-8.882	/	( (54.252	+	27.518)	/ 2 )
	=	-8.882	/	40.885
	=	-21.72 %

Neos Therapeutics's ROCE % of for the quarter that ended in Sep. 2020 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2020 )		(Q: Jun. 2020 )		(Q: Sep. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2020 )		(Q: Jun. 2020 )		(Q: Sep. 2020 )
	=	-11.616	/	( ( (62.689 - 60.86)	+	(64.584 - 67.161) )	/ 2 )
	=	-11.616	/	( ( 1.829	+	-2.577 )	/ 2 )
	=	-11.616	/	-0.374
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

Neos Therapeutics (NAS:NEOS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neos Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neos Therapeutics (Neos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2940 N. Highway 360, Grand Prairie, TX, USA, 75050

Website

http://www.neostx.com

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.

Executives

Alan L Heller	director	BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille	director
John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr.	director	852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin	director, officer: Chief Executive Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli	officer: SVP & General Counsel	700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell	officer: Chief Commercial Officer	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg	officer: Chief Executive Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking	officer: VP, Regulatory Affairs	C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens	officer: Chief Tech/Operations Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355